JP2022513798A5 - - Google Patents
Info
- Publication number
- JP2022513798A5 JP2022513798A5 JP2021533535A JP2021533535A JP2022513798A5 JP 2022513798 A5 JP2022513798 A5 JP 2022513798A5 JP 2021533535 A JP2021533535 A JP 2021533535A JP 2021533535 A JP2021533535 A JP 2021533535A JP 2022513798 A5 JP2022513798 A5 JP 2022513798A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- composition according
- peptide
- item
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024214382A JP2025038018A (ja) | 2018-12-14 | 2024-12-09 | トランスフェリン受容体標的ペプチド |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862779885P | 2018-12-14 | 2018-12-14 | |
| US62/779,885 | 2018-12-14 | ||
| US201962836520P | 2019-04-19 | 2019-04-19 | |
| US62/836,520 | 2019-04-19 | ||
| PCT/US2019/066376 WO2020124032A1 (en) | 2018-12-14 | 2019-12-13 | Transferrin receptor targeting peptides |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024214382A Division JP2025038018A (ja) | 2018-12-14 | 2024-12-09 | トランスフェリン受容体標的ペプチド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022513798A JP2022513798A (ja) | 2022-02-09 |
| JP2022513798A5 true JP2022513798A5 (https=) | 2022-12-20 |
| JP7664158B2 JP7664158B2 (ja) | 2025-04-17 |
Family
ID=71077078
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021533535A Active JP7664158B2 (ja) | 2018-12-14 | 2019-12-13 | トランスフェリン受容体標的ペプチド |
| JP2024214382A Pending JP2025038018A (ja) | 2018-12-14 | 2024-12-09 | トランスフェリン受容体標的ペプチド |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024214382A Pending JP2025038018A (ja) | 2018-12-14 | 2024-12-09 | トランスフェリン受容体標的ペプチド |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220048961A1 (https=) |
| EP (1) | EP3893913B1 (https=) |
| JP (2) | JP7664158B2 (https=) |
| CN (1) | CN113329758A (https=) |
| AU (1) | AU2019398467A1 (https=) |
| CA (1) | CA3120466A1 (https=) |
| IL (1) | IL283839A (https=) |
| WO (1) | WO2020124032A1 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020232247A1 (en) | 2019-05-14 | 2020-11-19 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| IL298999A (en) | 2020-06-11 | 2023-02-01 | Provention Bio Inc | Methods and compositions for the prevention of type 1 diabetes |
| CN111647048B (zh) * | 2020-06-22 | 2021-04-02 | 中国科学院昆明动物研究所 | 干扰多肽在制备抗SARS-CoV-2药物中的应用 |
| WO2021258250A1 (zh) | 2020-06-22 | 2021-12-30 | 中国科学院昆明动物研究所 | 干扰多肽在制备抗SARS-CoV-2药物中的应用 |
| JP2022014707A (ja) * | 2020-07-07 | 2022-01-20 | 東亞合成株式会社 | キャリアペプチドフラグメントおよびその利用 |
| AU2021315533A1 (en) * | 2020-07-30 | 2023-02-16 | University Of Washington | Transferrin receptor binding proteins |
| CN117279618A (zh) * | 2020-11-30 | 2023-12-22 | 弗莱德哈钦森癌症中心 | 用于靶标分子的选择性耗竭的组合物和方法 |
| EP4298132A4 (en) * | 2021-02-23 | 2025-03-12 | Ichilov Tech Ltd. | FUSION PROTEINS FOR THE TREATMENT OF CNS DISEASES |
| JP2024520444A (ja) | 2021-05-24 | 2024-05-24 | プロヴェンション・バイオ・インコーポレイテッド | １型糖尿病を治療するための方法 |
| WO2023023031A2 (en) * | 2021-08-17 | 2023-02-23 | Blaze Bioscience, Inc. | Transferrin receptor targeting peptide oligonucleotide complexes and methods of use thereof |
| CN117957240A (zh) * | 2021-08-19 | 2024-04-30 | 肽梦想株式会社 | 人转铁蛋白受体结合肽 |
| KR102934033B1 (ko) * | 2021-10-01 | 2026-03-06 | 서울대학교산학협력단 | 혈액 뇌장벽 투과용 펩타이드 및 이의 용도 |
| EP4467573A4 (en) * | 2021-10-15 | 2025-08-06 | Yichen Therapeutics Ltd | BISPECIFIC BINDING MOLECULE |
| CN115160408B (zh) * | 2022-06-29 | 2025-04-22 | 辽宁天增祥生物科技有限公司 | 降压肽或中国蛤蜊降压肽提取物及其应用 |
| CN115925981B (zh) * | 2022-08-18 | 2025-05-23 | 河南工业大学 | 一种特异性靶向革兰氏阴性菌的抗菌肽及其应用 |
| EP4626906A1 (en) * | 2022-11-29 | 2025-10-08 | Vacino Biotech Co., Ltd. | Transporter peptides and application thereof |
| TW202434613A (zh) * | 2023-02-17 | 2024-09-01 | 日商肽夢想股份有限公司 | 人類運鐵蛋白受體結合肽 |
| WO2024238304A2 (en) * | 2023-05-12 | 2024-11-21 | University Of Washington | Improved transferrin receptor binding proteins |
| WO2025042711A1 (en) * | 2023-08-18 | 2025-02-27 | Eli Lilly And Company | Engineered transferrin receptor binding peptides as well as methods of making and using the same |
| CN119896743B (zh) * | 2023-10-26 | 2025-09-26 | 华南理工大学 | 一种基质金属蛋白酶响应的多功能仿生铁蛋白纳米材料及其制备方法与应用 |
| WO2025090121A1 (en) * | 2023-10-27 | 2025-05-01 | Yale University | Conjugate and methods of treatment |
| WO2025096245A1 (en) * | 2023-11-02 | 2025-05-08 | The Regents Of The University Of California | Design rules for endosomal escape |
| CN120647772A (zh) * | 2024-03-15 | 2025-09-16 | 迦进生物医药(上海)有限公司 | 特异性结合转铁蛋白受体的多肽及其应用 |
| CN120459270A (zh) * | 2025-05-16 | 2025-08-12 | 中国人民解放军海军军医大学 | OpiCa1或其纳米脂质体在制备治疗和/或预防心肌纤维化相关疾病药物中的应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002236499A8 (en) * | 2000-11-30 | 2009-12-03 | Uab Research Foundation | Receptor-mediated uptake of peptides that bind the human transferrin receptor |
| CA2512717A1 (en) * | 2003-01-09 | 2004-07-29 | Arizeke Pharmaceuticals Inc. | Compositions and methods for targeted biological delivery of molecular carriers |
| US7973019B1 (en) * | 2007-10-03 | 2011-07-05 | Alcon Research, Ltd. | Transferrin/transferrin receptor-mediated siRNA delivery |
| EP2822577B1 (en) * | 2012-02-15 | 2019-02-06 | Bioverativ Therapeutics Inc. | Recombinant factor viii proteins |
| WO2013177062A2 (en) * | 2012-05-21 | 2013-11-28 | Genentech, Inc. | Methods for improving safety of blood-brain barrier transport |
| CN103897033A (zh) * | 2014-03-31 | 2014-07-02 | 中国药科大学 | 转铁蛋白受体TfR特异性结合肽及其应用 |
| EP3218411B1 (en) * | 2014-11-14 | 2022-01-12 | Ossianix, Inc. | Variable new antigen receptors (vnars) directed against transferrin receptor (tfr) and their use |
| HUE057952T2 (hu) * | 2015-06-24 | 2022-06-28 | Hoffmann La Roche | Anti-transzferrin receptor antitestek testreszabott affinitással |
| EP3494216B1 (en) | 2016-08-06 | 2025-10-15 | Ossianix, Inc. | In vivo methods for selecting peptides that cross the blood brain barrier, related compositions and methods of use |
-
2019
- 2019-12-13 CA CA3120466A patent/CA3120466A1/en active Pending
- 2019-12-13 AU AU2019398467A patent/AU2019398467A1/en not_active Abandoned
- 2019-12-13 WO PCT/US2019/066376 patent/WO2020124032A1/en not_active Ceased
- 2019-12-13 JP JP2021533535A patent/JP7664158B2/ja active Active
- 2019-12-13 CN CN201980089966.8A patent/CN113329758A/zh active Pending
- 2019-12-13 EP EP19897452.9A patent/EP3893913B1/en active Active
- 2019-12-13 US US17/312,703 patent/US20220048961A1/en active Pending
-
2021
- 2021-06-09 IL IL283839A patent/IL283839A/en unknown
-
2024
- 2024-12-09 JP JP2024214382A patent/JP2025038018A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022513798A5 (https=) | ||
| Dal Corso et al. | A non-internalizing antibody-drug conjugate based on an anthracycline payload displays potent therapeutic activity in vivo | |
| Thomas et al. | Antibody–drug conjugates for cancer therapy | |
| Nasiri et al. | Antibody‐drug conjugates: Promising and efficient tools for targeted cancer therapy | |
| US11345715B2 (en) | Biologically active molecules, conjugates thereof, and therapeutic uses | |
| ES2543201T3 (es) | Métodos y agentes que mejoran la dirección a las células tumorales que expresan CD138 | |
| ES2938186T3 (es) | Procedimiento de fabricación selectiva de un conjugado anticuerpo-fármaco | |
| CN106456794B (zh) | 接头药物与抗体的位点特异性缀合以及所得adc | |
| US20200360474A1 (en) | Receptor-based antagonists of the programmed cell death 1 (pd-1) pathway | |
| EP2233156B1 (en) | Use of aprotinin polypeptides as carriers in pharmaceutical conjugates | |
| US20230295285A1 (en) | Methods of reversing cachexia and prolonging survival comprising administering a gdf15 modulator and an anti-cancer agent | |
| ES2382058T3 (es) | Combinación de una proteína de fusión de un anticuerpo dirigido contra el EDB de la fibronectina-IL-2, y una molécula de unión a los linfocitos B, progenitores de los linfocitos B y/o sus homólogos cancerosos | |
| TW202019487A (zh) | 抗體-藥物結合物及微管蛋白抑制劑之組合 | |
| IL322218A (en) | Compositions containing an antibody against lag-3 or an antibody against lag-3 and an antibody against pd-1 or pd-l1 | |
| CA2748291A1 (en) | Cancer treatment | |
| JP2016514132A5 (https=) | ||
| JP2019524713A5 (https=) | ||
| JP2020517658A5 (https=) | ||
| Amani et al. | ADCs, as novel revolutionary weapons for providing a step forward in targeted therapy of malignancies | |
| JP7608336B2 (ja) | 中枢神経系原発リンパ腫の併用治療 | |
| JP2024542021A (ja) | ペイロードのｉｎ ｖｉｖｏ標的化送達用のテトラジンコンジュゲート | |
| JP2021521100A (ja) | 癌免疫療法のためのチェックポイント阻害剤の細胞集団を介した送達 | |
| Wu | Enhancement of immunotoxin activity using chemical and biological reagents | |
| JP6782932B2 (ja) | Ｎｐｒ−ａアゴニストの新規用途 | |
| Koli et al. | Lung cancer receptors and targeting strategies |